Everest Medicines’ etrasimod meets primary endpoint in Phase 3 UC trial
In the study, etrasimod treatment produced a clinically meaningful and statistically significant improvement in primary endpoint as well…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
01 Dec 23
In the study, etrasimod treatment produced a clinically meaningful and statistically significant improvement in primary endpoint as well…
01 Dec 23
The Phase 1 open-label trial studied the delivery of QN-01 via the RespiRx device for three different nicotine…
29 Nov 23
V116 is an investigational, 21-valent vaccine, currently in late-stage trial for prevention of invasive pneumococcal disease and pneumococcal…
28 Nov 23
In the trial, Dupixent reduced moderate or severe acute COPD exacerbations by 34% over 52 weeks and led…
28 Nov 23
The drug achieved the primary endpoint of progression-free survival and extended the time to disease progression or death…
22 Nov 23
Next-generation propellant technology has the potential to reduce greenhouse gas emissions from Ventolin (salbutamol) inhaler by approximately 90%
21 Nov 23
The new business, Evinova, will provide digital health solutions to pharma, biotech, and clinical research organisations (CROs) to…
15 Nov 23
The combination failed to improve progression-free survival (PFS) against CRT alone in NSCLC patients and showed an enhanced…
15 Nov 23
The combination of Xarelto and Aspirin consistently lowered major adverse limb events (MALE) and major cardiovascular events (MACE)…
14 Nov 23
Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI…